This isHOMEinCorporate InformationinHistorypages.

History

1939 Establishment of Koa Kagakukogyo Co., Ltd. Initiation of the manufacturing and sales of nourishing food article.
1940 Company name changed to Koa Eiyokagaku Kenkyusho Co., Ltd.
1941 Initiation of the manufacturing and sales of drugs for the organ systems of the human body.
1943 Capital investment by Tanabe Seiyaku Co., Ltd and a marketing alliance.
1946 Company name changed to Nihon Eiyokagaku Co., Ltd.
1949 Powdered agar for the detection of bacteria, the first product of the field successfully commercialized in Japan.
1950 Commercialization of "SS agar medium" for the detection of dysentery bacillus, etc.
1955 Inauguration of the monthly publication "Modern Media".
1961 Establishment of Clinical Laboratory Division.
Initiation of R&D of in vitro diagnostics.
1965 Completion of the first-Stage of construction of the Nogi Plant in Nogi-City, Tochigi.Initiation of production.
Inauguration of the Saburo Kojima Memorial Society.
1969 Company name Changed to Eiken Chemical Co., Ltd. in recognition of its 30th anniversary.
1975 Establishment of the Oji branch in kita-ku, Tokyo.
1980 Completion of the new headquarter building in Bunkyo-ku, Tokyo.
1984 Completion of the first-stage of construction of the Nasu Plant in Otawara-City, Tochigi.
1987 Completion of the second-stage of construction of the Nasu Plant.
Initiation of the production of angiographic contrast mediums.
Commencement of the sales of the angiographic contrast medium "Hexabrix 320".
1989 Completion of the Immuno-serologic Factory (the 8th Nogi Plant Factory). Initiation of production.
1990 Stocks listed in the second section of the Tokyo Stock Exchange.
Establishment of the Ryogoku branch in Sumida-ku, Tokyo.
1992 Establishment of the Biochemical Research Laboratory in Nogi-machi, Tochigi.
1993 Establishment of the Kurozumi Medical Foundation (K M F).
First issuance of unsecured convertible bonds.
1996 Completion of the new plant for contrast media in Nasu Factory.
1997 Commencement of the sales of "Feridex", an MRI enhancement material.
1998 Development of novel DNA amplification "LAMP" method and filing of its patent applications.
2000 Sales alliance for microbiology test-related products with Becton Dickinson Japan Co., Ltd.
Commencement of the sales of OC-Sensor µ, a fully automated fecal occult blood analyzer.
2001 Initiation of direct sales of in vitro diagnostics.
Commencement of the sales of Magnescope Syringe for MRI material.
Commencement of the sales of OC-Sensor neo, a fully automated fecal occult blood analyzer.
Establishment of Eiken Logistics Service Co., Ltd. (E L S).
2002 Stocks listed on the first section of the Tokyo Stock Exchange.
LAMP method patent granted in U.S.A. and Japan.
Commencement of the sales of novel "Loopamp Bovine Embryo Sexing Kit" and its "End Point Turbidimeter".
Commencement of online service of the LAMP Primer design support software.
Sales alliance with Sysmex for automated urine analyzers and test strips for urinalysis in China.
Commencement of the sales of novel "Lumispot ‘Eiken’ HCV Antigen".
2003 Commencement of the sales of "Loopamp Salmonella Screening Kit", "Loopamp Verotoxin-producing Escherichia coli Screening Kit", and "Loopamp Verotoxin Typing Kit".
Agreement with FUJIHIRA INDUSTRY on the distribution of Loopamp Bovine Embryo Sexing Kit in China.
Agreement with POLYMEDCO inc. on the sales and purchase of reagents and analyzers for the fecal occult blood test in North American market.
Commencement of the sales of "Loopamp SARS-CoV detection kit".
2004 Established EIKEN SHANGHAI CO., LTD. in China.
Commencement of the sales of "Loopamp Primer Set for West Nile Virus" as the first primer set.
Commencement of the sales of "Centrifugal machine EC-10" and "Blood collecting set ‘Eiken’ " as devices for mailing medical checkup.
Acquired FDA approval for FOBT reagent and analyzer, which have been available for sale.
2005 Commencement of the sales of automated urine analyzer "US-1000".
Transition to Company with Committee System.
Collaboration to develop rapid diagnostic test for Tuberculosis with The Foundation for Innovative New Diagnostics (FIND).
Eiken obtained ISO13485:2003 and ISO9001:2000 certification.
Strategic partnership agreement between Eiken and Hitachi High-Technologies Corporation.
2006 Strategic partnership agreement between Eiken and Otsuka Pharmaceutical Co., Ltd.
2007 Tetsuya Teramoto became President and CEO.
Merged EIKEN KIZAI CO., LTD. which was previously a subsidiary.
Establishment of BRAVE CIRCLE Committee. (It became NPO Corporation in 2009.)
2008 Development of the procedure for ultra rapid extraction method "PURE method" for LAMP
Relocated our headquarter in Taito-ku, Tokyo.
2009 Establishment of new management vision ‘EIKEN WAY’ and ‘EIKEN ROAD MAP 2009’.
2010 Commencement of the sales of various LAMP products. (Detection for H1pdm, Mycoplasma, Legionella, HSV, FulA)
Obtainment of ISO14001 certification.
2011 Commencement of the sales of “Loopamp MTBC Detection Kit”.
Establishment of Europe office in Amsterdam (the Netherlands).
2012 Completion of construction of OMC building in Nogi Division.
Disposal of Oji Office.
Closing of the Togane Factory.
Commencement of the sales of "BLEIA-1200", the fully-automatic biochemistry photogenetic immunoassay device.
2013 Commencement of the sales of three hepatitis screening kits for "BLEIA-1200".
2014 Commencement of the sales of "DPS 192iX", the drug sensitivity tests device and "Dry Plate'EIKEN'(192)".
Morifumi Wada became President and CEO.